(p)ppGpp and its role in bacterial persistence: new challenges

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue10
UDC.journalTitleAntimicrobial Agents and Chemotherapy
UDC.startPagee01283-20
UDC.volume64
dc.contributor.authorPacios Santamaría, Olga
dc.contributor.authorBlasco, Lucía
dc.contributor.authorBleriot Rial, Inés
dc.contributor.authorFernández-García, Laura
dc.contributor.authorAmbroa, Antón
dc.contributor.authorZamora López, María José
dc.contributor.authorBou, Germán
dc.contributor.authorCantón, Rafael
dc.contributor.authorGarcía-Contreras, Rodolfo
dc.contributor.authorWood, Thomas K.
dc.contributor.authorTomás, María
dc.date.accessioned2026-03-02T08:37:49Z
dc.date.available2026-03-02T08:37:49Z
dc.date.issued2020-09-21
dc.descriptionReview
dc.description.abstract[Abstract] Antibiotic failure not only is due to the development of resistance by pathogens but can also often be explained by persistence and tolerance. Persistence and tolerance can be included in the "persistent phenotype," with high relevance for clinics. Two of the most important molecular mechanisms involved in tolerance and persistence are toxin-antitoxin (TA) modules and signaling via guanosine pentaphosphate/tetraphosphate [(p)ppGpp], also known as "magic spot." (p)ppGpp is a very important stress alarmone which orchestrates the stringent response in bacteria; hence, (p)ppGpp is produced during amino acid or fatty acid starvation by proteins belonging to the RelA/SpoT homolog family (RSH). However, (p)ppGpp levels can also accumulate in response to a wide range of signals, including oxygen variation, pH downshift, osmotic shock, temperature shift, or even exposure to darkness. Furthermore, the stringent response is not only involved in responses to environmental stresses (starvation for carbon sources, fatty acids, and phosphates or heat shock), but it is also used in bacterial pathogenesis, host invasion, and antibiotic tolerance and persistence. Given the exhaustive and contradictory literature surrounding the role of (p)ppGpp in bacterial persistence, and with the aim of summarizing what is known so far about the magic spot in this bacterial stage, this review provides new insights into the link between the stringent response and persistence. Moreover, we review some of the innovative treatments that have (p)ppGpp as a target, which are in the spotlight of the scientific community as candidates for effective antipersistence agents.
dc.description.sponsorshipThis study was funded by grant PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund, A way of Making Europe, Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006 and RD16/0016/0011), and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). L. Fernández-García was supported by postdoctoral fellowship from the Diputation A Coruña (Xunta Galicia). T.J.K. is supported by a National Health and Medical Research Council Early Career Fellowship (GNT1088448).
dc.identifier.citationPacios O, Blasco L, Bleriot I, Fernandez-Garcia L, Ambroa A, López M, Bou G, Cantón R, Garcia-Contreras R, Wood TK, Tomás M. (p)ppGpp and Its Role in Bacterial Persistence: new Challenges. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01283-20.
dc.identifier.doi10.1128/AAC.01283-20
dc.identifier.issn1098-6596
dc.identifier.urihttps://hdl.handle.net/2183/47539
dc.language.isoeng
dc.publisherAmerican Society of Microbiology
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI16%2F01163/ES/"Terapia FÁGICA CLÍNICA: Nuevos retos"/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00878/ES/"TRATAMIENTOS ANTI-TOLERANCIA Y%2FO ANTI-PERSISTENCIA BACTERIANA: CLAVES PARA LA LUCHA FRENTE A BACTERIAS RESISTENTES"/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0011/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/
dc.relation.urihttps://doi.org/10.1128/AAC.01283-20
dc.rights.accessRightsopen access
dc.subject(p)ppGpp
dc.subjectTA systems
dc.subjectPersistence
dc.subjectSlow growth
dc.title(p)ppGpp and its role in bacterial persistence: new challenges
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Pacios_(p)ppGp_2020.pdf
Size:
462.43 KB
Format:
Adobe Portable Document Format